Envista (NVST) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
7 Apr, 2026Voting matters and shareholder proposals
Election of eight director nominees for a one-year term expiring at the 2027 annual meeting.
Ratification of Ernst and Young LLP as the independent registered public accounting firm for the year ending December 31, 2026.
Advisory approval of named executive officer compensation (say-on-pay).
Advisory vote on the frequency of future say-on-pay votes, with the board recommending an annual vote.
Consideration of any other business that may properly come before the meeting or any adjournment.
Board of directors and corporate governance
Eight nominees are presented for election to the board, each for a one-year term.
Audit committee and external auditor matters
Proposal to ratify Ernst and Young LLP as the external auditor for the upcoming fiscal year.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Envista
- Annual meeting to vote on directors, auditor, executive pay, and ESG priorities.NVST
Proxy filing7 Apr 2026 - Double-digit core growth and margin gains in 2025 set the stage for continued momentum in 2026.NVST
Q4 20256 Feb 2026 - Targets 2%-4% core growth and 7%-10% EPS growth, driven by innovation and operational discipline.NVST
CMD 20253 Feb 2026 - Q2 loss of $1.15B on impairments; sales, margins fell, but cash flow and Q4 outlook improved.NVST
Q2 20242 Feb 2026 - Q3 2024 sales fell 5.3%, net income dropped, but full-year guidance was reaffirmed.NVST
Q3 202417 Jan 2026 - Dental market growth, innovation, and operational execution drive double-digit financial gains.NVST
44th Annual J.P. Morgan Healthcare Conference13 Jan 2026 - Stable dental market, growth investments, and China VBP shape outlook for 2025.NVST
7th Annual Evercore ISI HealthCONx Conference12 Jan 2026 - Strategic investments and stable market trends position the business for renewed growth.NVST
43rd Annual J.P. Morgan Healthcare Conference 202510 Jan 2026 - Q1 2025 core sales rose 0.2% with stable guidance and effective risk mitigation.NVST
Q1 202523 Dec 2025